Royalty PharmaRPRX
RPRX
About: Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Employees: 99
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
160% more call options, than puts
Call options by funds: $89M | Put options by funds: $34.2M
65% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 51
21% more capital invested
Capital invested by funds: $8.18B [Q4 2024] → $9.86B (+$1.68B) [Q1 2025]
7% more funds holding
Funds holding: 412 [Q4 2024] → 440 (+28) [Q1 2025]
7% more repeat investments, than reductions
Existing positions increased: 156 | Existing positions reduced: 146
0.92% more ownership
Funds ownership: 72.13% [Q4 2024] → 73.04% (+0.92%) [Q1 2025]
22% less funds holding in top 10
Funds holding in top 10: 9 [Q4 2024] → 7 (-2) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$42
13%
upside
Avg. target
$48
29%
upside
High target
$54
45%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Citigroup Geoff Meacham | 13%upside $42 | Buy Maintained | 22 Jul 2025 |
Morgan Stanley Terence Flynn | 45%upside $54 | Overweight Maintained | 10 Jul 2025 |
Financial journalist opinion
Based on 5 articles about RPRX published over the past 30 days
Neutral
Zacks Investment Research
8 hours ago
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
1 week ago
Royalty Pharma Declares Third Quarter 2025 Dividend
NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share.
Neutral
GlobeNewsWire
1 week ago
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company's Board of Directors
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Carole Ho and Elizabeth (Bess) Weatherman to its Board of Directors, effective immediately. Carole Ho is Chief Medical Officer and Head of Development at Denali Therapeutics, a biopharmaceutical company focused on neurodegenerative diseases. Bess Weatherman is a Special Limited Partner of Warburg Pincus LLC, a leading global private equity firm focused on growth investing.
Neutral
GlobeNewsWire
2 weeks ago
Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025
NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2025 financial results on Wednesday, August 6, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.
Neutral
Seeking Alpha
4 weeks ago
Royalty Pharma: Attractive Acquisition With Upside Risk/Reward On Current Pipeline
Royalty Pharma is less exposed to MFN drug pricing risks, offering downside protection in a volatile policy environment. The Revolution Medicines royalty deal provides near-term upside and de-risks pipeline assets, with pivotal data expected in 2026. We forecast 2025 EPS of $4.53 and raise our target price to $45.3, reflecting strong earnings and capital deployment.
Positive
Reuters
1 month ago
Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug
Royalty Pharma said on Tuesday will pay up to $2 billion to Revolution Medicines to support the companies' plans for global development and commercialization of the experimental cancer drug daraxonrasib.
Neutral
GlobeNewsWire
1 month ago
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion
NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a $2 billion funding arrangement with Revolution Medicines, consisting of a synthetic royalty of up to $1.25 billion on daraxonrasib and a senior secured loan of up to $750 million. These funds will support Revolution Medicines' plans for global development and commercialization of daraxonrasib and its pipeline programs for patients with RAS-addicted cancers.
Neutral
GlobeNewsWire
1 month ago
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 2:00 p.m. ET.
Neutral
GlobeNewsWire
2 months ago
Royalty Pharma Completes the Acquisition of Its External Manager
NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC (“RP Management”). The acquisition received overwhelming support from Royalty Pharma's shareholders, with 99.9% of votes cast in favor of the transaction.
Neutral
GlobeNewsWire
2 months ago
Royalty Pharma to Present at Upcoming Investor Conferences
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May:
Charts implemented using Lightweight Charts™